Your browser doesn't support javascript.
loading
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas, Alberto J; Napoli, Sara; Cascione, Luciano; Barnabei, Laura; Sartori, Giulio; Cannas, Eleonora; Gaudio, Eugenio; Tarantelli, Chiara; Mensah, Afua A; Spriano, Filippo; Zucchetto, Antonella; Rossi, Francesca M; Rinaldi, Andrea; Castro de Moura, Manuel; Jovic, Sandra; Bordone Pittau, Roberta; Stathis, Anastasios; Stussi, Georg; Gattei, Valter; Brown, Jennifer R; Esteller, Manel; Zucca, Emanuele; Rossi, Davide; Bertoni, Francesco.
Affiliation
  • Arribas AJ; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Napoli S; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Cascione L; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Barnabei L; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Sartori G; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Cannas E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Gaudio E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Tarantelli C; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Mensah AA; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Spriano F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Zucchetto A; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Rossi FM; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Rinaldi A; Centro di Riferimento Oncologico di Aviano - CRO, Aviano, Italy.
  • Castro de Moura M; Centro di Riferimento Oncologico di Aviano - CRO, Aviano, Italy.
  • Jovic S; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Bordone Pittau R; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.
  • Stathis A; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Stussi G; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Gattei V; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Brown JR; Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
  • Esteller M; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Zucca E; Centro di Riferimento Oncologico di Aviano - CRO, Aviano, Italy.
  • Rossi D; Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Bertoni F; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.
Mol Cancer Ther ; 23(3): 368-380, 2024 Mar 04.
Article in En | MEDLINE | ID: mdl-38052765
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, B-Cell / Antineoplastic Agents Limits: Humans Language: En Journal: Mol Cancer Ther Year: 2024 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, B-Cell / Antineoplastic Agents Limits: Humans Language: En Journal: Mol Cancer Ther Year: 2024 Document type: Article